Last checked at 
17 Jan 2019 09:00
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Â
Â
Portfolio Update as at 31 December 2018
Â
Net Assets | £209m |
Net Assets per share | 556p |
Share price | 570p |
Total value of unquoted investments | £30m |
Total number of portfolio companies | 61 |
Dividend | 4% of NAV per annum |
Â
Top Ten Quoted Investments
Â
Company Name | % NAV |
Incyte | 6.1 |
Vertex | 5.6 |
Celgene | 5.4 |
Genmab | 5.1 |
Gilead Sciences | 5.0 |
Regeneron | 4.4 |
Exelixis | 4.4 |
Illumina | 3.8 |
Neurocrine | 3.4 |
Biomarin | 3.0 |
 | ----------- |
Total | 46.2 |
Â
Geographical Allocation | % NAV |
US & Canada | 87 |
Europe | 13 |
 | ----------- |
Total | 100 |
Â
Â
Quoted/Unquoted Allocation | % NAV |
Quoted | 85 |
Unquoted | 15 |
 | ----------- |
Total | 100 |
Â
Â
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 44 |
Mid Cap =USD1-10BN | 33 |
Small Cap | 23 |
 | ----------- |
Total | 100 |
Â
Â
NAV % by Therapeutic Areas | % NAV |
Oncology | 35 |
Rare diseases | 21 |
CNS | 10 |
Ophthalmology | 5 |
Infectious Diseases | 5 |
Tools | 4 |
Inflammation | 3 |
Medtech | 3 |
Metabolic | 0 |
Other | 14 |
 | ----------- |
Total | 100 |
Â
Â
Â
BNP Paribas Secretarial Services Limited
Company Secretary
Â
17 JANUARY 2019